The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (33 analysts) rates it buy, with a mean price target of $334.
Expedia Group
EXPE · a US exchange · USD · Market cap $30.1B · 16,000 employees
Expedia Group, Inc.
PASS · Titan Ethical · score 75.4Price as of 19 Nov 2026Daily close, not a live quote
Screened 2026-11-19 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price239.19 USD at the 19 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 19 Nov 2026
- Our regime readDistribution, as of 16 Nov 2026
- Ethical screenPasses, score 75.4 out of 100
- OptionsOpen interest leans to puts (put/call 2.49)
- Last reviewed19 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $409.52 to $478.38, base estimate $412.50 (screen dated 2026-11-19).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 2.49, read 2026-11-19
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Expedia Group holds its Distribution at $239.19. The statistical read favours the sellers, held for 6 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 6 days |
| Price at the screen | $239.19 |
| Valuation | 14.88 trailing · 10.22 forward price to earnings |
| Values screen | PASS · score 75.4 |
| Beta | 1.39 |
Five Screens: EXPE's Results
PASS. All five recorded results clear their limits.
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 26.24% | Below 33% | Pass |
| Interest-bearing cash | 1.31% | Below 33% | Pass |
| Receivables | 39.17% | Below 49% | Pass |
| Revenue purity | 1.73% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Clears, in Plain English
Expedia clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 26%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when EXPE's ethical verdict changes
Today EXPE passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 19 Nov 2026: it trades at roughly a 42% discount to our $412.50 fair value, narrow competitive moat, 11.90% revenue growth.
Model construction and limits: fair-value methodology.
Fair value range in USD, drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. A 42.0% discount to the base estimate.
Third-party analyst targets: 35 covering, consensus Buy. The average target sits +38% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $412.50, with a range of $409.52 to $478.38, dated to the 2026-11-19 screen.
How our estimate and third-party targets differ.
The Business, in Plain WordsHoliday bookings keep the cash flowing
When families finally book that summer holiday, Expedia sits in the middle taking a cut. Revenue is rising 15 percent, the forward multiple sits at just 11.7 times, and return on equity hits 71 percent, all while the shares trade at a 32 percent discount to our fair value. The business clears the ethical screen and still carries a narrow moat in a market where scale matters.
A 10 percent profit margin and buy-rated analyst consensus point to steady demand recovery in travel services. The setup looks attractive on paper for a consumer cyclical name that has rebuilt its balance sheet after the pandemic shock.
Travel spending remains sensitive to recessions and fuel spikes, and a narrow moat leaves room for rivals to chip away at margins. Peak-cycle earnings can flatten fast, so the low multiple may simply reflect that risk rather than a bargain. Analysis, not advice.
| Forward P/E | 10.2xfairly priced for its growth rate |
| Trailing P/E | 14.9xreasonably valued |
| EPS, trailing | 17.06 |
| EPS, forward | 24.82 |
| Revenue growth | +11.9%steady growth |
| Profit margin | 13.0%thin but positive margins |
| Return on equity | 76.7%an exceptional return on shareholder capital |
| FCF yield | 7.80% |
| Dividend yield | 0.78% |
| Debt to equity | 1.95a meaningful debt load worth watching |
| Current ratio | 0.77below 1: short-term bills exceed liquid assets |
| Beta | 1.39moves a little more than the market |
| Short interest, float | 0.09% |
| 52-week range | 185.34 - 342.00 |
| Moat | NARROW |
| Market cap | $30.1B |
| Employees | 16,000 |
EXPE-specific watchpoints · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 11.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (35 analysts) rates it buy, with a mean price target of $333.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (34 analysts) rates it buy, with a mean price target of $337. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (34 analysts) rates it buy, with a mean price target of $338. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (34 analysts) rates it buy, with a mean price target of $338. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (34 analysts) rates it buy, with a mean price target of $338. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (34 analysts) rates it buy, with a mean price target of $338. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (34 analysts) rates it buy, with a mean price target of $338. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (34 analysts) rates it buy, with a mean price target of $338. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (34 analysts) rates it buy, with a mean price target of $338. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- EXPE vs. ABNB: Which Stock Is the Better Value Option? Yahoo Finance · 7d ago
- 4 GARP Stocks That Investors Can Scoop Up for Maximum Returns Yahoo Finance · 7d ago
- Google faces renewed challenge over $1.66bn advertising fine Yahoo Finance · 7d ago
- How Has Booking Holdings' Story Changed? Yahoo Finance · 8d ago
- United Is the Latest to Block AI Agents Like Muse. These Stocks Have a Mini Relief Rally. Yahoo Finance · 9d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-15 | DILLER BARRY | Chairman of the Board | 8,185 | · | |
| 2026-05-15 | ANDERSEN DEREK | Chief Financial Officer | 7,223 | · | |
| 2026-05-15 | GORIN ARIANE | Chief Executive Officer | 16,552 | · | |
| 2026-05-15 | SOLIDAY LANCE A | Officer | 1,215 | · | |
| 2026-05-15 | DZIELAK ROBERT J | Officer | 5,837 | · | |
| 2026-04-15 | DZIELAK ROBERT J | Officer | 2,304 | · | |
| 2026-03-13 | SCHENKEL SCOTT F | Chief Financial Officer | 7,626 | · | |
| 2026-03-13 | DZIELAK ROBERT J | Officer | 4,631 | · | |
| 2026-03-04 | DZIELAK ROBERT J | Officer | 8,225 | $1,816,244 | |
| 2026-02-13 | DILLER BARRY | Chairman of the Board | 9,256 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-05-27 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-05-15 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-05-06 | John Fetterman | Democrat | buy | 1K–15K |
| 2026-05-01 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-04-13 | Ro Khanna | Democrat | Sale | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $291.72 | -15.7% | · | $843 | -15.7% |
| 2 months | $279.35 | -12.0% | · | $880 | -12.0% |
| 3 months | $323.70 | -24.1% | $0.48 | $761 | -23.9% |
| 6 months | $213.89 | +14.9% | $0.96 | $1,154 | +15.4% |
| 1 year | $238.23 | +3.2% | $1.84 | $1,039 | +3.9% |
| 2 years | $177.93 | +38.1% | $3.04 | $1,398 | +39.8% |
| 3 years | $134.52 | +82.7% | $3.04 | $1,850 | +85.0% |
| 5 years | $172.76 | +42.3% | $3.04 | $1,440 | +44.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever EXPE does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.